[18F]FDG-PET/CT evaluation
METABOLIC DISEASE
Response evaluation with [18F]FDG-PET/CT after 6 weeks of treatment was available for 29 patients. Fifteen patients (52%) had a partial metabolic response, nine (31%) had stable metabolic disease, four (14%) had progressive metabolic disease, and one (3%) had a mixed metabolic response. Fourteen/29 patients (48%) had a non-concordant response according to PERCIST vs. RECIST (response was upgraded in nine patients by the PERCIST criteria). Patients with partial metabolic response had PFS 12.6 months (95% CI: 7.7–17.5 months) and OS 31.4 months (95% CI: 9.4–53.5 months). For patients with stable metabolic response and progressive metabolic disease, PFS was 8 months (95% CI: 5.2–10.8 months) and 3.3 months (95% CI: 0–11.8 months), and OS 13.9 months (95% CI: 0–31.2 months) and 23.1 months, respectively. Tumour-to-liver SUV